Cymbalta
Cymbalta
$10,000.00
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain.
Publisher: Datamonitor Healthcare
- Description
- Contents
Drug Overview
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain. The drug is also marketed for the treatment of women with moderate to severe stress urinary incontinence in Europe under the brand name Yentreve.
Cymbalta was formerly marketed by Boehringer Ingelheim in a number of European countries under the brand name Xeristar, although Eli Lilly has since reacquired exclusive rights to develop and market duloxetine. In Japan – where Cymbalta was not launched until April 2010 – the drug is jointly marketed by Shionogi and Eli Lilly for the treatment of depression and depressive symptoms.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Cymbalta : Neuropathic pain
15 Cymbalta : Depression
LIST OF FIGURES
8 Figure 1: Cymbalta for neuropathic pain – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Cymbalta for neuropathic pain
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Cymbalta for neuropathic pain
12 Figure 4: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26
20 Figure 5: Cymbalta for depression – SWOT analysis
21 Figure 6: Datamonitor Healthcare’s drug assessment summary for Cymbalta in depression
22 Figure 7: Datamonitor Healthcare’s drug assessment summary for Cymbalta in depression
LIST OF TABLES
6 Table 1: Cymbalta drug profile
7 Table 2: Cymbalta Phase III data in neuropathic pain syndromes
13 Table 3: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 4: Cymbalta drug profile
18 Table 5: Overview of pivotal trial data for Cymbalta in depression
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
